UB Paderborn / Katalog / Suche / in CDI

SOT101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity

Frontiers in immunology, 2022-10, Vol.13, p.989895-989895

2022

Volltextzugriff (PDF)

713 Nanrilkefusp alfa, a high-affinity IL-15Rβγ agonist, promotes an innate and adaptive anti-tumour inflammatory environment as single agent or combined with anti-PD-1 in patients with advanced cancers

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A808-A808

2023

Volltextzugriff (PDF)

1087 SOT201 is a novel cis-acting immunocytokine targeting IL-15Rβγ to reinvigorate PD-1+tumor infiltrating lymphocytes and potentiate anti-tumor efficacy

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1196-A1196

2023

Volltextzugriff (PDF)

563 Pharmacodynamics and pharmacokinetics of SO-C101 in cynomolgus monkeys

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A339-A339

2020

Volltextzugriff (PDF)

Tumor-localized costimulatory T cell engagement by the 4-1BB/HER2 bispecific antibody-Anticalin fusion PRS-343

Clinical cancer research, 2019-10, Vol.25 (19), p.5878-5889

2019

Volltextzugriff (PDF)

Abstract 1204: SO-N102, a novel CLDN18.2-targeting antibody-drug conjugate with strong anti-tumor effect in various solid tumors expressing low target levels

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1204-1204

2021

Volltextzugriff (PDF)

Abstract 6686: SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.6686-6686

2020

Volltextzugriff (PDF)

Elarekibep (PRS-060/AZD1402), a new class of inhaled Anticalin medicine targeting IL-4Ra for type 2 endotype asthma

Journal of allergy and clinical immunology, 2023-04, Vol.151 (4), p.966-975

2023

Volltextzugriff (PDF)

Abstract 3775: Use of RLI-15 a clinical grade fusion protein with IL-15 superagonistic activity for the activation of anti-tumor immune response

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3775-3775

2018

Volltextzugriff (PDF)

A Phase I Study Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of the Hepcidin Antagonist PRS-080#022. Results from a Randomized, Placebo Controlled, Double-Blind Study Following Single Administration to Healthy Subjectsa

Blood, 2015-12, Vol.126 (23), p.536-536

2015

Volltextzugriff (PDF)

Therapeutic antibodies to human L1CAM: functional characterization and application in a mouse model for ovarian carcinoma

Cancer research (Chicago, Ill.), 2010-03, Vol.70 (6), p.2504-2515

2010

Volltextzugriff (PDF)

Abstract 556: Costimulatory T-cell engagement by the HER2/CD137 bispecific PRS-343 leads to strong antitumor effect in humanized mouse model

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.556-556

2016

Volltextzugriff (PDF)

Abstract 556: Costimulatory T-cell engagement by the HER2CD137 bispecific PRS-343 leads to strong antitumor effect in humanized mouse model

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.556-556

2016

Volltextzugriff (PDF)

Abstract 3510: SOT201 is a novel targeted IL-15Rbg agonist to alleviate PD-1-mediated immune cell suppression and potentiate anti-tumor efficacy

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.3510-3510

2022

Volltextzugriff (PDF)

Expression of different CD8 isoforms on distinct human lymphocyte subpopulations

European journal of immunology, 1991-08, Vol.21 (8), p.1793-1800

1991

Volltextzugriff (PDF)

Abstract C205: Costimulatory T-cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.C205-C205

2015

Volltextzugriff (PDF)

Abstract CT040: SOT101, an IL-2/IL-15 Rβγ superagonist, in combination with pembrolizumab in patients with advanced solid tumors: Interim safety and efficacy results from the AURELIO-03 dose escalation trial

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT040-CT040

2022

Volltextzugriff (PDF)

562 SO-C101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A596-A596

2020

Volltextzugriff (PDF)

Abstract B016: Costimulatory T-cell engagement by PRS-343, a CD137 (4-1BB)/HER2 bispecific, leads to tumor growth inhibition and TIL expansion in humanized mouse model

Cancer immunology research, 2016-11, Vol.4 (11_Supplement), p.B016-B016

2016

Volltextzugriff (PDF)

Abstract B023: Costimulatory T-cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein based on Anticalin® technology

Cancer immunology research, 2016-01, Vol.4 (1_Supplement), p.B023-B023

2016

Volltextzugriff (PDF)

Efficacy of oncolytic herpesvirus NV1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cells

Human gene therapy, 2006-12, Vol.17 (12), p.1241

2006

Volltextzugriff (PDF)

Therapeutic Antibodies to Human L1 CAM: Functional Characterization and Application in a Mouse Model for Ovarian Carcinoma

Cancer research (Chicago, Ill.), 2010, Vol.70 (6), p.2504-2515

2010

Volltextzugriff (PDF)

Costimulatory T cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein

Journal for immunotherapy of cancer, 2015-11, Vol.3 (Suppl 2), p.P187-P187, Article P187

2015

Volltextzugriff (PDF)

Der Arzneimittelmarkt in der Bundesrepublik Deutschland — Kritische Anmerkungen

Kosten und Effizienz im Gesundheitswesen, 2018, Vol.4, p.283-290

Originally published 1985, 2018

Volltextzugriff (PDF)

A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients

Clinical cancer research, 1997-02, Vol.3 (2), p.221-226

1997

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

SOT101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity

713 Nanrilkefusp alfa, a high-affinity IL-15Rβγ agonist, promotes an innate and adaptive anti-tumour inflammatory environment as single agent or combined with anti-PD-1 in patients with advanced cancers

1087 SOT201 is a novel cis-acting immunocytokine targeting IL-15Rβγ to reinvigorate PD-1+tumor infiltrating lymphocytes and potentiate anti-tumor efficacy

563 Pharmacodynamics and pharmacokinetics of SO-C101 in cynomolgus monkeys

Tumor-localized costimulatory T cell engagement by the 4-1BB/HER2 bispecific antibody-Anticalin fusion PRS-343

Abstract 1204: SO-N102, a novel CLDN18.2-targeting antibody-drug conjugate with strong anti-tumor effect in various solid tumors expressing low target levels

Abstract 6686: SO-C101 displays strong anti-tumor effect in TC-1 and TRAMP-C2 tumor mice and in combination with PD-1 blockade prevents tumor development in a NK and CD8+ T cells dependent manner

Elarekibep (PRS-060/AZD1402), a new class of inhaled Anticalin medicine targeting IL-4Ra for type 2 endotype asthma

Abstract 3775: Use of RLI-15 a clinical grade fusion protein with IL-15 superagonistic activity for the activation of anti-tumor immune response

A Phase I Study Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of the Hepcidin Antagonist PRS-080#022. Results from a Randomized, Placebo Controlled, Double-Blind Study Following Single Administration to Healthy Subjectsa

Therapeutic antibodies to human L1CAM: functional characterization and application in a mouse model for ovarian carcinoma

Abstract 556: Costimulatory T-cell engagement by the HER2/CD137 bispecific PRS-343 leads to strong antitumor effect in humanized mouse model

Abstract 556: Costimulatory T-cell engagement by the HER2CD137 bispecific PRS-343 leads to strong antitumor effect in humanized mouse model

Abstract 3510: SOT201 is a novel targeted IL-15Rbg agonist to alleviate PD-1-mediated immune cell suppression and potentiate anti-tumor efficacy

Expression of different CD8 isoforms on distinct human lymphocyte subpopulations

Abstract C205: Costimulatory T-cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein

Abstract CT040: SOT101, an IL-2/IL-15 Rβγ superagonist, in combination with pembrolizumab in patients with advanced solid tumors: Interim safety and efficacy results from the AURELIO-03 dose escalation trial

562 SO-C101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity

Abstract B016: Costimulatory T-cell engagement by PRS-343, a CD137 (4-1BB)/HER2 bispecific, leads to tumor growth inhibition and TIL expansion in humanized mouse model

Abstract B023: Costimulatory T-cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein based on Anticalin® technology

Efficacy of oncolytic herpesvirus NV1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cells

Therapeutic Antibodies to Human L1 CAM: Functional Characterization and Application in a Mouse Model for Ovarian Carcinoma

Costimulatory T cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein

Der Arzneimittelmarkt in der Bundesrepublik Deutschland — Kritische Anmerkungen

A sensitive ELISPOT assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients

Suchergebnisse filtern